9.24
+0.09(+0.98%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
257
First IPO Date
December 21, 2020
| Name | Title | Pay | Year Born |
| Dr. Yinxiang Wang | Executive Chairman & Chief Executive Officer | 3.14M | 1965 |
| Ms. Xiaojie Wang | Executive Director & President of Administration | 2.5M | 1965 |
| Ms. Yunyan Hu | Executive Vice President & Executive Director | 2.68M | 1962 |
| Dr. Andrea Wang-Gillam M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Global Head of R&D | 0 | 1971 |
| Ms. Yanping Wang | Executive Vice President of Non-Clinical R&D | 0 | N/A |
| Mr. Ming Fai Chung CPA | Joint Company Secretary | 0 | 1979 |
| Ms. Yuli Ding | Executive Vice President of Clinical Development | 0 | N/A |
| Ms. Tao Yang | Vice President of Human Resources | 0 | N/A |
| Ms. Qing Xue | Joint Company Secretary | 0 | 1989 |
| Dr. Haijun Wang | Senior Vice President of Information & Data Management | 0 | N/A |
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.